Leerink Partnrs Weighs in on Bio-Techne Co.’s Q1 2025 Earnings (NASDAQ:TECH)

Bio-Techne Co. (NASDAQ:TECH) – Equities research analysts at Leerink Partnrs dropped their Q1 2025 earnings per share (EPS) estimates for Bio-Techne in a research note issued on Wednesday, September 18th. Leerink Partnrs analyst P. Souda now forecasts that the biotechnology company will post earnings of $0.34 per share for the quarter, down from their previous estimate of $0.36. The consensus estimate for Bio-Techne’s current full-year earnings is $1.71 per share. Leerink Partnrs also issued estimates for Bio-Techne’s Q2 2025 earnings at $0.34 EPS, FY2025 earnings at $1.69 EPS, Q1 2026 earnings at $0.44 EPS, Q2 2026 earnings at $0.45 EPS and Q4 2026 earnings at $0.62 EPS.

Other equities research analysts have also recently issued research reports about the company. Benchmark restated a “buy” rating and issued a $95.00 target price on shares of Bio-Techne in a research note on Tuesday, August 13th. Royal Bank of Canada reduced their target price on shares of Bio-Techne from $72.00 to $70.00 and set a “sector perform” rating for the company in a report on Thursday, August 8th. Finally, Robert W. Baird lifted their price target on shares of Bio-Techne from $81.00 to $82.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Bio-Techne presently has a consensus rating of “Moderate Buy” and an average price target of $80.60.

Bio-Techne Stock Up 5.0 %

TECH stock opened at $80.36 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.87 and a quick ratio of 2.75. The stock has a market capitalization of $12.75 billion, a P/E ratio of 63.78, a P/E/G ratio of 5.06 and a beta of 1.27. Bio-Techne has a fifty-two week low of $51.79 and a fifty-two week high of $85.57. The business has a 50-day moving average of $75.23 and a 200-day moving average of $73.96.

Bio-Techne (NASDAQ:TECH) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.49 earnings per share for the quarter, meeting the consensus estimate of $0.49. Bio-Techne had a net margin of 14.50% and a return on equity of 12.88%. The company had revenue of $306.10 million during the quarter, compared to analysts’ expectations of $306.49 million. During the same quarter in the prior year, the company earned $0.56 earnings per share. The business’s quarterly revenue was up 1.6% compared to the same quarter last year.

Institutional Investors Weigh In On Bio-Techne

Hedge funds have recently bought and sold shares of the company. Sanctuary Advisors LLC bought a new stake in Bio-Techne in the second quarter valued at approximately $564,000. Quarry LP raised its stake in Bio-Techne by 2,275.6% in the 2nd quarter. Quarry LP now owns 974 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 933 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in Bio-Techne by 12.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,917 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 205 shares during the last quarter. Creative Planning boosted its position in Bio-Techne by 4.4% during the second quarter. Creative Planning now owns 33,942 shares of the biotechnology company’s stock worth $2,432,000 after purchasing an additional 1,437 shares during the period. Finally, Peloton Wealth Strategists increased its holdings in shares of Bio-Techne by 53.3% in the second quarter. Peloton Wealth Strategists now owns 4,600 shares of the biotechnology company’s stock valued at $330,000 after purchasing an additional 1,600 shares during the last quarter. 98.95% of the stock is currently owned by institutional investors and hedge funds.

Bio-Techne Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 30th. Stockholders of record on Monday, August 19th were paid a dividend of $0.08 per share. The ex-dividend date was Monday, August 19th. This represents a $0.32 annualized dividend and a dividend yield of 0.40%. Bio-Techne’s dividend payout ratio is presently 25.40%.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.